Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial

Mustang Bio Inc MBIO has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL).
The data were presented at the European Hematology Association 2021 Virtual Congress.
Updated data included safety and efficacy data from the cell manufacturing process modified to combine the culture of CD4+ and CD8+ cells.
In the 15 patients treated, the overall response rate (ORR) was 93% (14/15) with a complete response (CR) rate of 67% (10/15).
In 11 patients with follicular lymphoma (FL), ORR and CR were 91% (10/11) and 82% (9/11), respectively.
As of the time of the EHA2021 presentation, all patients who achieved CR remained in remission.
One patient with FL had an initial partial response with a later disease progression, had a spontaneous CR, and remains in remission.
The patient with CLL also had a CR and undetectable measurable residual disease in peripheral blood and bone marrow on day 28.
From a safety profile perspective, cytokine release syndrome occurred in 6 patients, primarily mild or moderate.
The company will host a Key opinion leader webinar on June 15, 2021, at 1 p.m. ET.
Price Action: MBIO shares are up 6.3% at $4.05 during the premarket session on the last check Friday.